Metabolic activity of neutrophilic granulocytes and possible ways of its correction in patients with acute coronary syndrome
Ryzhkova NA, Havrylenko TI, Parkhomenko OM, Kozhukhov SM
M.D. Strazhesko Institute of Cardiology, AMS of Ukraine, Kyiv
The present study aimed to investigate the metabolic activity of neutrocytes and the action of corvitin on the level of super-oxide anion and myeloperoxidases of cells in vitro with the calculation of index of consumption of myeloperoxidase in patients with ST-elevation acute coronary syndrome. Patient were divided into 2 groups according to the level of superoxide anion. Group 1 included the patients (68 %) with the initially low level of superoxide anion, and adding of corvitin to the cells of such patients promoted normalization of this index. In this group we observed also neutrocytosis, low index of consumption of myeloperoxidase and a high level of this enzyme in general population of neutrocytes. Group 2 included patients (32 %) with initially normal level of superoxide anion. In this group, corvitin did not influence substantially this factor. Such patients had a level of myeloperoxidase within control values and the index of consumption of this enzyme was also within control values. The analysis of hospital period showed that the patients of group 1 had a higher frequency of ventricular tachycardia / ventricular fibrillation, paroxysms of atrial fibrillation, bundle-branch blocks and worsening of the kidney function. We suppose that a low level of superoxide anion in neutrocytes play a major role in the development of complications in patients with acute coronary syndrome. An intravenous administration of corvitin was effective in restoring the metabolic activity of neutrocytes.
acute coronal syndrome, neutrocytes, quercetinum.
- Kremneva LV Leukocytosis as an indicator of CHD risk . Therap. archive. 2004. N 11. P. 30-35.
- Mayanskii DN Chronic inflammation. M .: Medicine, 1991. 272 p.
- Mayansky D.N., Mayanskaya S.D. The role of neutrophils in ischemic and reperfusion myocardial damage . Therap. archive. 2001. N 12. p. 84-88.
- Moibenko A.A., V.E.Dosenko, A.N.Parkhomenko. Endogenous mechanisms of cardioprotection as a basis for pathogenetic therapy of heart disease. K .: Sciences. opinion, 2008. 520 p.
- Parkhomenko OM, Amosova KM, Dyak GV, Goloborodko BI, Irkin OI, Koval OA, Kopitsa MP .. Netyazhenko VZ, Sledzewska I .K., Sokolov Yu.M., Tashchuk VK, Shumakov VO. Clinical recommendations for the diagnosis and treatment of acute myocardial infarction. Ukr. cardiol. . 2009. N 2 (thematic appendix). Pp. 4-23.
- Pinegin BV, Mayansky AN Neutrophils: structure and functions . Immunology. 2007. N 6. P. 374-382.
- Ryzhkova NA Features of the functional state of immunocompetent cells in acute coronary syndrome . Immunology and Allergology. 2006. N 4. pp. 21-25.
- Alyasin S., Amin R. Intracellular myeloperoxidas in myocardial infarction .Shiraz E-Med. J. 2005. 6. P.312-320.
- Bergt C, Pennathur S., Fu X. , Byun J., O'Brien K., McDonald Th.O., Singh P., Anantharamaiah G.M., Chait A., Brunzell J., Geary R.L., Oram J.F. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport . PNAS. 2004. 101. P.13032-13037.
- Bodi V., Sanchis J, Nunez J., Rumiz E., Mainar L., Lopez-lereu M.P., Monmeneu J.V., Oltra R., Forteza M.J., Chorro F.J., Llacer A. Post-reperfusion lymphopenia and microvascular obstruction in ST-seg-ment elevation acute myocardial infarction . Rev. Esp. Cardiol. 2009. 62 (10). P.1109-1117.
- Bodi V., Sanchis J, Nunez J. , Mainar L., Minana G., Benet I., Solano C, Chorro F.J., Llacer A. Uncontrolled immune response in acute myocardial infarction: Unraveling the thread . Amer. Heart J. 2008 156. P.1065-1073.
- Cascao R., Rosario H.S., Fonseca J.E. Neutrophils: warriors and commanders in immune mediated inflammatory diseases . Acta Reumatol. Port. 2009. 34. P.313-326.
- Hansson G.K. Inflammation, atherosclerosis and coronary artery deseases . N. Engl. J. Med. 2005. 352. P.1685-1695.
- Kozhukhov S., A. Parkhomenko. Administration of 5-lipoxygenaze inhibitor quercetin in patients with acute myocardial infarction and elevated white blood cells count: impact on necrotic zone and cardiac hemodynamics. In: Materials of 1st Congress of Acute Cardiac Care Working Group of European Society of Cardiology "Acute Cardiac Care 2004". Rome, 2004. P.58.
- Kozhukhov S., A.Parkhomenko. Myocardial protection by intravenous 5-lipoxygenase inhibitor Quercetin administration before primary angioplasty in patients with acute myocardial infarction: short-term results an open blind randomized trial . J. Amer. Coll. Cardiol. 2007. 49(9), Suppl. A. P.226A.
- Klebanoff S.J. Myeloperoxidase: friend and foe . J. Leucoc. Biol. 2005. 77. P.598-625.
- Nambi V. The use of myeloperoxidase as a risk marker for atherosclerosis . Cur. Ather. Rep. 2005. 7. P.127-131.
- Nichols S., Hazen S. The role of myeloperoxidase in pathogenesis of coronary artery disease . Jap. J. Infect. Dis. 2004. 57. P.21-22.
- Nunez J., Nunez E, Bodi V. , Sanchis J., Minana G., Mainar L., Santas E., Melros P., Rumiz E., Darmofal H., Heatta A.M., Llacer A. Usefulness of the neutrophil to lymphocyte ratio in predicting long-term mortality in ST segment elevation myocardial infarction . Amer. J. Cardiol. 2008. 101. P.747-752.
- Parkhomenko A., Kozhukhov S., Gurjeva O. Clinical efficacy of intravenous lipoxygenase inhibitor quercetin in patients with acute ST-segment elevation myocardial infarction: results of a prospective randomized open-label trial . Sem. Cardiol. 2005. 11(N 4). P.154-158.
- Van de Werf F., Bax J., Betriu A., Blomstrom-Lundquist C., Crea F., Falk V., Filippatos G., Fox K., Huber K., Kastrati A., Rosengren A., Steg P.G., Tubaro M., Verheugt F., Weidinger F., Weis M. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the task force on the management of st-segment elevation acute myocardial infarction of the European Society of Cardiology . Eur. Heart J. 2008. 29(23). P. 2909-2945.